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ABSTRACT
Since the 1918 flu pandemic, the novel human coronavirus outbreak COVID-19 has been the fifth known pandemic. COVID-19 was first identified 
in Wuhan, China, and later spread across the world. It is an infectious disease caused by the coronavirus 2 (SARS-CoV-2) extreme acute respiratory 
syndrome virus. The patients exhibit flu-like symptoms, including dry cough, sore throat, high fever, and trouble in breathing. Despite too much 
affords, there is no appropriate treatment or medication which is a successful COVID-19 therapy. A variety of candidate drugs are being used for the 
treatment and reviewed. This involves clinically accessible medications that are being repurposed for the treatment of COVID-19, such as chloroquine, 
hydroxychloroquine, and lopinavir/ritonavir. This review describes the different aspects of corona such as history, origin and spread, its types, life 
cycle, epidemiology, pathogenesis, diagnosis, treatment, and precautions. This review makes us understand what type of virus is this and how we can 
take precautions to protect us from this life-threatening virus. There is an immediate need to prepare our young generation to fight against any such 
catastrophe in the future, if any, of science and technology. There is no reason to worry and to fight this epidemic, careful prevention and control are 
necessary. This article can help to create public awareness, knowledge, avoiding, handling, and treating COVID-19.
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INTRODUCTION
Coronavirus disease (COVID-19) has been a recently discovered 
coronavirus-caused communicable disease. This disease has become the 
fifth documented pandemic since the 1918 flu pandemic. The general 
public infected with the COVID-19 virus will experience mild to moderate 
respiratory illness and recover with non-special treatment. Coronavirus 
(CoV) falls within the class of Nidovirales within the genus coronavirus 
belongs to the family Coronaviridae. The Coronaviridae family could 
also be divided into Coronavirinae and Torovirinae but may be further 
categorized into alpha, beta, gamma, and delta. Coronavirus is small in 
size (65–125 nm in diameter) and contains a single-stranded RNA as a 
nucleic filament, varying in size from 26 to 32 kb long [1-3]. Projections 
on its surface provide with a crown-like appearance under the electron 
microscope; hence, the term is a coronavirus. Four coronavirus viruses, 
namely, HKU1, NL63, 229E, and OC43, are in human circulation and 
typically cause mild respiratory illness. Coronavirus recombination rates 
are very high because of persistent transcription errors, high mutation 
rates, and RNA dependent RNA polymerase (RdRP) leaps. The broad 
scope of COVID-19 extends from moderate, self-limiting tract disease 
to merciless chronic pneumonia, multiple organ failure, and death. Be 
fully educated of the COVID-19 virus, the illness it triggers, and the 
way it progresses is that the only approach to discourage and hamper 
transmission. The infection is transmitted due to near communication 
with an infectious individual, susceptible to coughing, sneezing, nasal 
droplets, or aerosols that spread from humans to humans [4]. Such 
aerosols may enter the lungs through the nose or mouth through 
inhalation. Secure yourself from contamination by washing your hands 
regularly or employing a rub hooked into alcohol, and not touching your 
face, maintaining a distance from person to person, avoid direct contact 
with the surface area and wear a mask while going out to public places. 
After recovery from coronavirus, patients experience seizures as a side-
effect of this disease. It also causes reproductive system issues in both 
males and females. In males, it leads to a decrease in sperm count, and 
in females, it causes infertility. They also have to suffer from the bone 
disorder include osteoarthritis. According to the WHO report, there 
have been 19,936,210 confirmed cases of COVID-19, including 732,499 
deaths, till the date of August 11, 2020, in all over the world [5,6].
HISTORY
Researchers first described a coronavirus in 1937, isolating one 
that was to blame for a form of bronchitis in birds with the power to 
devastate poultry supplies. In 1960, the primary case of coronavirus 
was reported as cold in human beings. Approximately 500 people were 
classified as a flu-like condition, consistent with the Canadian report 
2001. 17–18 instances of those were reported as polymerase chain 
reaction contaminated with a coronavirus strain. Before 2002, corona 
was considered a typical non-fatal virus [7,8]. However, as time passes, 
it had been getting more severe and eventually become the concerned 
issue. In 2002–2003, when a unique SARS-CoV of the β genera induced 
SARS with a place to begin and reservoirs as bats, transmitted to 
humans through the conciliator host of civet cats, it contaminated 8422 
people in China and metropolis and induced 916 deaths with a rate of 
11%. Therefore, in 2004 the planet Health Organization and disease 
control and prevention centers proclaimed a “national emergency.” 
A couple of decades later, in 2012, the Middle East coronavirus 
respiratory syndrome (MERS-CoV), also of bat origin, appeared in the 
Kingdom of Saudi Arabia with premedical camels because of the host, 
impacting 2494 people and causing 858 deaths (fatality rate 34%). 
Previously, at the top of 2019, Wuhan, an emerging industrial center 
in China, witnessed a virus of a unique coronavirus that killed quite 
eighteen hundred people and contaminated over seventy thousand 
people during the epidemic’s 1st 50 days. This virus has been identified 
as belonging to the b category of coronaviruses [9,10]. COVID-19 was 
first identified and isolated from pneumonia patent belongs to Wuhan, 
China. The globe Health Organization (WHO) announced on January 
30, 2020, that the COVID-19 epidemic represented a public health 
emergency of international significance (PHEIC). The Director-General 
of the WHO proclaimed the COVID-19 epidemic a plague on March 11, 
2020, cantered on the elevated rate of world transmission and also the 
seriousness of COVID-19 [11,12].
ORIGIN AND SPREAD
In December 2019, adults in Wuhan, the capital city of the province 
of Hubei and a significant transportation center of China, started 
reporting serious pneumonia of uncertain origin to local hospitals. 
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2020.v13i12.39823
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China told the WHO about the epidemic on December 31, 2019, and 
therefore the human seafood shops were closed on January 1, 2020. 
The virus was identified as a coronavirus on January 7th that has about 
95% similarities with coronary bat virus and about 70% resemblance 
to SARS-CoV-2. Samples taken from the things and animals on the 
Huanan seafood market were also healthy, suggesting that this virus 
comes from seafood. First, the number of cases began to extend slowly, 
indicating that transfer from individual to individual happened as a 
number of these cases was not available within the animal market. The 
primary cause of fatality was registered on January 11th due to Chinese 
heavy travel during the Chinese year, which sparked the pandemic [13]. 
Wuhan’s population is about 11 million citizens, where they were held 
in detention with limits on entry and exit. The virus quickly spread 
to several cities within the province of Hubei. Certain cases emerged 
(very fast) in Japan, South Korea, and Thailand, aside from China, 
on January 23rd. Cases began to develop rapidly and tests of models 
recorded a pandemic doubling time of 1.8 days. Indeed, on Lincoln’s 
Birthday, China, modified the concept of reported cases to incorporate 
patients with negative/pending molecular tests together with 
COVID-19 surgical, radiological, and epidemiological characteristics 
contributing to in rising of 15,000 in at some point in incidents. As of 
March 05, 2020, 96,000 incidents were registered worldwide (80,000 
in China) and 87 other countries and 1 overseas travel (696 within the 
Diamond Princess Ocean liner parked off the coast of Japan). This can 
be necessary to recollect that although the number of reported cases 
has recently declined in China; they need dramatically risen in many 
countries such as South Korea, Italy, and Iran. India, which had recorded 
just three cases before March 02, 2020, also witnessed a sudden spurt 
within the incidents. By March 05, 2020, 29 cases had been reported; in 
Italian tourists and their contacts mostly in Delhi, Jaipur, and Agra [14].
An Indian who traveled back from Wien and revealed a big number 
of faculty children during a birthday celebration at a city hotel was 
mentioned in one event. Many of the persons were quarantined for his 
or her safety and to forestall the spread of the virus. The quantity of 
reported cases has risen significantly in emerging countries, including 
Iran, Asian countries, and Italy, although at the identical time, it is 
beginning to decline in China. COVID-19 incidents in China today have a 
very cheap development rate relative to other high-profile nations, and 
also, the epidemic seems to be almost in check [15].
TYPES OF CORONAVIRUS
The First Human CoVs (HCoVs) was founded in 1965. The type of virus 
is called CoVs; because of the projection-like surface, which similar 
to a crown. These CoVs are 26 to 32 kb lengthen positive-strand RNA 
viruses. It causes severe respiratory and neurological disease. This CoV 
contains four genera such as Alpha, Beta, Gama, and Delta. Of 4 genera, 
alpha and beta produce human respiratory illness.
Coronaviruses belong to the subfamily Coronavirinae in the family 
Coronaviridae. Different types of human coronaviruses vary in how 
severe the resulting disease becomes and how far they can spread. 
Coronaviruses are named for the crown-like spikes on their surface. 
There are four main sub-groupings of coronaviruses, known as alpha, 
beta, gamma, and delta [16-18].
Human coronaviruses were first identified in the mid-1960s. Doctors 
currently recognize seven types of coronavirus that can infect humans. 
The seven coronaviruses that can infect people are (Fig. 1):
Common coronavirus
1. 229E (alpha coronavirus)
2. NL63 (alpha coronavirus)
3. OC43 (beta coronavirus)
4. HKU1 (beta coronavirus).
Other human coronavirus
1. MERS-CoV (the beta coronavirus that causes Middle East respiratory 
syndrome, or MERS)
2. SARS-CoV (the beta coronavirus that causes severe acute respiratory 
syndrome, or SARS)
3. SARS-CoV-2 (the novel coronavirus that causes coronavirus disease 
2019, or COVID-19).
People around the world commonly get infected with human 
coronaviruses 229E, NL63, OC43, and HKU1. Sometimes coronaviruses 
that infect animals can evolve and make people sick and become a new 
human coronavirus. Three recent examples of this are 2019-nCoV, 
SARS-CoV, and MERS CoV. SARS-CoV-1, MERS-CoV, and SARS-CoV-2 are 
pathogenic and cause severe infections in humans following contact 
with the respective intermediate hosts (bats) (Fig. 2). However, HCoV-
229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1 do not appear to cause 
severe infections in humans [19].
LIFE CYCLE OF COVID-19
SARS-CoV-2 is getting into bind human cells angiotensin-converting 
enzyme 2 (ACE2). After binding of ACE2, the COVID-19 virus is entered 
into the cell through endocytosis (Fig. 2). This process is mediated 
by membrane-bound protease. It is known as transmembrane serine 
protease 2 (TMPRSS2), which is involved in cleaves the S protein for 
membrane fusion. Then, the COVID-19 viral RNA genome is entering 
into the intracellular compartment. The viral RNA is translated into 
the encoded structural and nonstructural proteins. The translation 
of the nonstructural proteins (Nsp1-16), replicas leads to in massive 
polypeptide chain, in which the 16 Nsp is cleaved. That process is 
regulated by host cell proteases, COVID-19 main protease, and papain-
like protease. On the other hand, the RNA-dependent RNA polymerase 
(RdRp) is involved in replicate the viral genome. End of this process, 
many structural and nonstructural proteins (Nsp1-16) are generated. 
This is accumulated to the endoplasmic reticulum membrane. These 
are packed in the Golgi apparatus for viral budding. Finally, through the 
exocytosis process, it targets to another host cell (Fig. 3) [20,21].
Fig. 1: Coronavirus families are four genera-human respiratory illness producing species (alpha and beta)
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EPIDEMIOLOGY OF COVID-19
The latest novel 2019 coronavirus disease (COVID-19) that induces 
pneumonia is a highly contagious illness, and the recent epidemic has 
infected a large portion of the world’s population. It was announced 
by WHO on January 30, 2020, as a global public health emergency of 
international significance. From its first epidemic site, Wuhan Area, it 
is now spreading quickly across Hubei province to other provinces in 
China and across the world. According to the WHO report, the outbreak 
is already spreading to over 117 countries as of March 12, 2020. More 
than 125,048 recorded COVID-19 cases have been detected since the 
start of the epidemic, and more than 4613 deaths have been documented 
worldwide. Among these, China reported the bulk (64.8%) among cases, 
while the remaining (35.2%) were found outside China. According to 
the WHO regular survey, the number of countries registering reported 
COVID-19 events is now rising periodically [22-30].
Males were most frequently influenced by the novel COVID-19, and 
the mean age range of patients is 49–59 years. Among adolescents, 
nearly all recorded incidents existed (median age 59 years). Older 
individuals are usually twice as prone to severe COVID-19 disease. 
Slightly more than 2% of patients were under the age of 18, of which 
<3% had serious or essential diseases. Based on the analysis conducted 
by Wu and McGoogan on 72,314 cases in China, COVID-19’s average 
case-fatality rate (CFR) was 2.3%. In such cases, the CFR was higher 
at 80 and above years of age (8.0%) and important COVID-19 cases 
(49.0%). Furthermore, the CFR was greater for people with pre-
existing comorbid conditions: 10.5% for coronary disease, 7.3% for 
asthma, 6.3% for a chronic pulmonary disorder, 6.0% for hypertension, 
and 5.6% for cancer. Notwithstanding far higher CFRs for SARS (9.6%) 
and MERS (34.4%), owing to the vast number of incidents, COVID-19 
resulted in more direct deaths. Both ages are susceptible to this lethal 
virus infection, it is transmitted by symptomatic patients in the process 
of coughing and sneezing by producing wide contaminated droplets 
and can disperse between 1-2 m and deposit on surfaces, but it may 
also occur from asymptomatic residents until symptoms begin.
As of December 2019, the first reports were registered. Five people were 
diagnosed with severe respiratory distress syndrome from December 
18, 2019, to December 29, 2019, and one of those patients died. By 
January 2, 2020, 41 hospitals admitted patients had been reported 
as having COVID-19 infection verified in the clinic, with fewer than 
half of these patients reporting chronic conditions, including asthma, 
hypertension, and cardiovascular disease. In that facility, these patients 
were believed to be contaminated, most possibly due to nosocomial 
infection by an unexplained mechanism. A disease epidemic that began 
from a small seafood market has expanded significantly to kill 84,970 
people in China and is correlated with 4645 deaths as of June 20, 2020. 
Fig. 2: Mode of coronavirus transmission from carriers to humans
Fig. 3: Life cycle of SARS-COV2
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There was a sharp increase in the number of COVID cases in China by 
February 29, 2020. A drop in the incidence of new incidents, though, 
continued to fall, contributing to a curve peak for the overall number 
of cases. The SARS-CoV-2 pandemic has infected 8,525,042 people and 
claimed 456,973 lives worldwide by June 20, 2020, according to the 
WHO situation estimates. Until now, the SARS-CoV-2 has been spread 
to more than 215 countries with disastrous effects in almost all of the 
world’s infected regions identified by the WHO [31].
In a survey involving 425 cases, the mean incubation period was 
5.2 days (95% CI 4.1–7.0 days) and the median incubation period was 
3.0 days (range 0–24 days) in another analysis focused on 1,324 cases. 
It could be likely that the sole instance, with outlying 24-day incubation 
duration, was, in reality, a second occurrence rather than a sole cycle of 
incubation for infection [32].
COVID-19’s incubation time is similar to other previous infectious viral 
diseases-SARS (2–7 days) and MERS-CoV (2–14 days) but is significantly 
greater than swine flu (1–4 days) and normal influenza (1–4 days). 
Research analyzing 88 importation cases of travel-related distribution 
reported a median incubation time of 6.4 days (2.1–11.1 days). The 
figures typically display a great deal of variation depending on the 
patient sample type and epidemiological characteristics, although 
when more evidence is available, more reliable results are expected to 
appear [33].
At present, October 8, 2020, we have 36,449,272 reported COVID-19 
incidents globally, including 1,061,489 deaths, spread as follows: North 
America: 9,327,415, South America: 8,459,726, Europe: 5,649,656, 
Africa: 1,546,091, Asia: 11,433,636, and Oceania: 32,027.
PATHOGENESIS OF COVID-19
The pathogenesis of COVID-19 is still uncertain and could involve the 
following factors: [34-40]
1. SARS-CoV-2 attaches through the coronavirus spike(S) protein to 
the angiotensin-converting enzyme-2 (ACE2) receptor to infiltrate 
alveolar epithelial cells to facilitate immediate toxicity and abnormal 
immune responses (Fig. 4). The caused systemic inflammation 
triggers a cytokine outbreak that induces pulmonary damage and 
people with serious illness evolve and suffer from respiratory failure.
2. Pathological findings revealed that the lungs of COVID-19 patients 
display diffuse alveolar disruption and hyaline membrane forming 
in the bloodstream, and lung pathology itself is close to that of SARS 
and Middle East respiratory syndrome (MERS).
3. ACE2 is also expressed in the kidneys, heart, lung, and intestines, 
and SARS-CoV-2 may invade cells in the aforementioned tissues 
to proliferate and destroy these organs resulting in multiple organ 
dysfunction syndromes (MODS).
4. In patients with severe COVID-19, which may be associated with poor 
outcomes, the levels of IL-2, IL-6, IL-7, IL-10, granulocyte colony-
stimulating factor, interferon gamma-induced protein 10, monocyte 
chemoattractant protein-1, macrophage inflammatory protein 1α, 
and tumor necrosis factor α are significantly high.
5. Excessive activation of lymphocytes in COVID-19 patients and a rise 
in pro-inflammatory CCR4+CCR6+Th17 cells facilitate immuno-
medicated injury, leading to increased intensity of mild disease and 
progression of single organ involvement to MODS. In particular, 
elderly people with reduced immunity are more susceptible to 
infection, and patients with comorbidity. 
SYMPTOMS OF COVID-19
Signs of COVID-19 infection have begun to appear after an incubation 
period of around 5.2 days. The time from COVID-19 symptoms attack to 
death ranged from 6 to 41 days, with 14 days average. The incubation 
period depends on the age of the patient, which is also dependent on 
the state of the patient’s immune system. Patients > 70 years old have 
shorter incubation times relative to patients below 70 years old [41-47].
Usually, COVID-19 causes flu-like symptoms such as fever (99%), 
chills, dry cough (59%), sputum (27%), exhaustion (70%), lethargy, 
arthralgia, myalgia (35%), anxiety, dyspnea (31%), nausea, vomiting, 
anorexia (40%), and diarrhea. Such symptoms may progress into 
pneumonia, chest pressure, chest discomfort, and breathing problems 
in the elderly and other patients with other chronic health conditions. 
It appears as if it begins with a fever and progresses to dry coughing. 
One week after diagnosis, the symptoms are severe and contribute 
to reduced breath, with nearly 20% of patients seeking care and 
prescription from the hospital. The COVID-19 disorder tends to seldom 
cause runny, sneezing, or sore throat (only around 5% of patients have 
these symptoms). Sneezing the sore cough and stuffy nose are usually 
common flu or cold signs. A lot of people may experience discomfort or 
hemoptysis, and others will even be asymptomatic. Mostly, Older people 
easily effected which are already prone to obesity, coronary disorder. 
And diabetes [48-51]. Cerebrovascular illness and extreme alveolar 
injury are more vulnerable to respiratory failure. In extreme situations, 
the initiation of illness may display accelerated development to organ 
failure (e.g., acute kidney damage, trauma, acute cardiac damage, 
acute respiratory distress syndrome [ARDS]), and death. Occasionally 
patients can experience reduced or high counts of white blood 
cells, thrombocytopenia, or lymphopenia, with elevated amounts of 
C-reactive protein and prolonged activated duration of thromboplastin. 
This is reported that 80% of affected cases are moderate, with typical 
fever and flu, so patients will recover at home. In brief, a patient with 
leukopenia or lymphopenia will be accused of developing upper 
respiratory tract symptoms and fever [52-56].
DIAGNOSIS
Diagnosis of suspicious infections should be made as quickly as 
possible to rapidly identify and monitor the infection. COVID-19 should 
be considered in any patient with fever and/or lower respiratory tract 
symptoms with all of the following risk factors in the previous 2 weeks: 
Near interaction with confirmed or reported cases in any area, 
especially in healthcare settings without proper protective equipment 
or long-term status in such settings, and living or traveling from well-
known locations where the disorder is an outbreak. Patients with 
extreme lower respiratory tract disease without alternate etiologies 
and a consistent infection history should be considered COVID19 unless 
otherwise reported [57,58].
To assist with COVID-19 dia0gnosis, clinical signs need to be evaluated. 
The WHO and the United States Centers for Disease Control and 
Prevention (CDC) have given preliminary updates on important clinical 
and epidemiological results of COVID-19. Extensive laboratory testing 
for confirming COVID-19 diagnosis should be required. RT-PCR can be 
used in isolated samples with swabs of the stomach, sputum, stool, and 
blood. Main laboratory admission findings include leukocytes below 
or beyond the normal range; neutrophils beyond normal range; and 
lymphocytes, hemoglobin, and platelets below normal range [59].
High levels of alanine aminotransferase, aspartate aminotransferase, 
C-reactive protein, creatine kinase, lactate dehydrogenase, blood 
urea nitrogen, and serum creatinine can be the main liver findings. 
Concerning the infection index, procalcitonin levels can surpass normal 
ranges [60].Fig. 4: Structure of SARS-COV-2
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Radiological studies can also assist in the diagnosis of virally 
compromised patients with pneumonia. In over 75% and 71% of 
adult patients, respectively, bilateral and multi-lobe involvement of the 
lungs was normal. In pediatric patients, the following guidelines for 
fast respiratory rate should be met for COVID-19 induced pneumonia 
diagnosis: ≥60 times/min for less than 2 months of age; ≥50 times/min 
for 2–12 months of age; ≥40 times/min for 1–5 years of age; and 
≥30 times/min for > 5 years of age (after removing fever and crying 
effects) [61-65].
DIFFERENTIAL DIAGNOSIS
Including viral respiratory infections caused by the SARS virus, influenza 
virus, parainfluenza virus, adenovirus, respiratory syncytial virus, and 
metapneumovirus can include a differential diagnosis. These patients 
have identical clinical characteristics, but in some cases, with increased 
or reduced leukocyte counts. Patients may also have pneumonia due 
to bacterial causes that may be caused by high fever and moist rale 
cough. Another common form of misrepresentation is mycoplasma 
pneumonia. For such patients, chest X-ray images may show reticular 
shadows and slight patchy or large consolidations. To this differential 
diagnosis, mycoplasma-specific IgM is helpful. Epidemiological 
treatment and the examination of blood or sputum will help to confirm 
the accurate diagnosis of COVID-19. COVID-19 cannot be isolated from 
these pathogens either clinically or by regular laboratory examination. 
Hence, the history of travel becomes significant. The travel past will, 
thus, become meaningless as the disease spreads [66,67].
TREATMENT
There is no precise treatment for coronavirus, but prevention, 
management, and supporting healthcare may provide relief in the 
outbreak of COVID-19. The first-line treatment is self-quarantining 
for at least 14 days and the cure is to keep a distance of at least 
three feet and sanitize yourself after every outing. However, some 
approaches have been or may be used to control this disease. These 
approaches may be categorized in Allopathic, Unani, and Homeopathic 
treatments. Allopathic treatment and management embrace medical 
care, blood vessel fluid infusion with life support in dangerous cases. 
It is additionally sensible to contact a healthful professional if the flue 
like symptoms prevails. In general, the Unani medicines (plant-based 
medicines) are nontoxic and with none facet effects [68]. Unani and 
Ayurvedic strategies of the treatment supported the plant materials. 
The various elements of the assorted plants are acknowledged for a 
protracted time for his or her anti-viral activities. The most necessary 
plants are liquorice, Allium cepa, Allium sativum, asterid dicot genus 
sanctum, asteroid dicot genus tenuiflorum, Madagascar pepper, 
magnoliid dicot genus verum, Daucus maritimus, turmeric, etc. A liquid 
extract of those plants in conjunction with juice and honey was found 
to be effective for contagion and customary cold virus infections. In 
medical care, arsenic at terribly low concentration is taken into account 
useful for many diseases together with infectious agent infections. 
Recently, the board of AYUSH, New Delhi, India, issued an order dater 
on January 30, 2020, to require prophylactic medication to avoid 
coronavirus infection. The board steered taking four pills of Arsenic 
Album-30 medication once daily in the empty abdomen for three days. 
Arsenic Album-30 is a very diluted arsenic and works as medical aid 
prevention. It is necessary to say here that there is no clinical proof for 
Arsenic Album-30 medication as a good medication [69,70].
Establishing a useful medicine against COVID-19 is desperately 
required. Variety of medication are claimed to be safe and economical 
by irregular controlled trials; but, solely 2 of that are allowed by 
government agency therefore far:
At terribly 1st time combination of two medicines was suggested for the 
treatment for corona that was 200 mg of hydroxychloroquine (3 times 
daily for 10 days) with 500 mg of azithromycin (only for 1st 5 days). 
However, it does not show any helpful results.
Earlier discovered drugs are used for the treatment of earlier symptoms 
such as antimalarial drugs salt and anti-inflammatory salt. The 
subsequent is an outline of the medicine being employed or undergoing 
trials at present. Once conducting varied tests to see the effectiveness of 
antimalarial drug salt (CQ) and anti-inflammatory salt (HCQ), they are 
presently used as first-line treatment medicine in most countries. The 
antimalarial drug is a previous drug used against protozoal infection 
that is cheap and safe for elder patients. Consistent with studies, 
compared with CQ, HCQ has fewer facet effects in semi-permanent 
use, fewer drug-drug interactions, and may be employed in higher 
doses. It is attainable that a mix of anti-inflammatory and azithromycin 
could have a positive result, particularly in severe cases. Despite the 
effectualness of those two-medicine within the recovery method, there 
are also some facet effects together with Gi responses, risk of internal 
organ arrhythmias, and risk of retinal damage, particularly with future 
use. Remdesivir may be a new medicine being beneath examination that 
inhibits infectious agent replication through premature termination of 
ribonucleic acid transcription and is capable of poignant a good variety 
of ribonucleic acid viruses. Many clinical trials have indicated the 
potency of Remdesivir within the treatment procedure [71,72].
Other antiviral agents that inhibit the proteinase activity of coronavirus 
and HIV in vitro or animal model studies are lopinavir (LPV) and 
antiviral (a nucleoside analog). No variations were determined 
throughout the infectious agent shedding once treatment with Kaletra 
(combined drug lopinavir and ritonavir). The European society of 
medical care medication (ESICM) does not advocate the routine use of 
Kaletra. Corticosteroids inhibit immune responses and microorganism 
clearance despite suppressing respiratory organ inflammation. There 
is no evidence-based reason to contemplate corticosteroids useful 
within the treatment method; rather, they are a lot of possibilities to 
be harmful. Interim steerage from WHO on the clinical management of 
severe acute infection (released March 13, 2020) suggests against the 
employment of corticosteroids once SARSCoV-2 infection is suspected, 
apart from exceptional circumstances, particularly severe cases that 
ought to be prescribed with care. Some medicine is still beneath 
investigation such as anti-influenza medicine, umifenovir, oseltamivir, 
and also the helpful treatments for severe acute respiratory syndrome 
and MERS (the alternative beta coronaviruses that unfold 20 years ago). 
Researchers are creating a nice effort to search out economical medicine 
exploitation, irregular management trials necessary before utilization. 
The worldwide unfold of COVID-19 has become a vital health issue. 
However, a lot of data is nonetheless to be nonheritable. Public health 
efforts are most required to limit the occurrence of the virus through 
human to human transfer, which looks to be the most effective approach 
within the current state of affairs. Meanwhile, there are no medicines 
that have been shown to prevent or cure the disease [73]. Recovered 
patients donated their plasma for the treatment of Covid patients.
To overcome this, coronavirus spread vaccination is important that 
will help to boost up the immune system against the virus so that we 
should not become sick. About 140 vaccines are under development 
and around two dozen are now being tested on people in clinical trials. 
Till now, only the oxford vaccine shows a good result in triggering 
the immune response and many countries considered it safe and 
effective against the virus, but now the preliminary trials of the Oxford 
AstraZeneca vaccine were temporarily stopped because a volunteer 
developed neurological symptoms, later found unrelated to the jab. 
Normally vaccine takes 1–2 years for its development, but due to the 
severe condition of the world, researchers tried their best to get it as 
soon as possible all over the world till the mid of the coming 2021 [74].
PRECAUTIONARY MEASURES AGAINST COVID-19
The degree of COVID-19 spread is currently around 5.3%, which could 
theoretically rise if precautionary steps are not taken into account. 
Consequently, global avoidance of the dissemination of COVID-19 is a 
critical and immediate priority. The diagnosis and treatment of persons 
with COVID-19 is a high priority to avoid the further transmission of 
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this disease. Self-quarantine, segregation of infectious persons, social 
distancing, proper personal hygiene (frequent handwashing with soap 
and water/alcohol-based sanitizers and avoiding touching the eyes, nose, 
and mouth), and use of personal protective equipment are examples of 
steps to prevent spreading. Any compound groups, called surfactants, are 
found in soap and are capable of neutralizing microbes such as SARS CoV-
2. This is because soap can be shaped into structures called micelles that 
capture viral matter and other biomaterials that are bubble-like. In soap 
lather, surfactants have their hydrophilic sections pointed outward and 
communicating with solvent and pointed inward with their hydrophobic 
heads. This removes the outer membrane of the coronavirus and 
encapsulates viral molecules inside micelles, rendering insoluble viral 
molecules readily soluble in water after around 20s and easily extracting 
them from the palms, surfaces, or other regions. Hence, surfactants in 
the soap can destroy and sequestrate viruses and other pathogens, while 
sanitizers and disinfectants are intended to kill SARS-CoV-2 [75,76].
CONCLUSION
The SARS-CoV-2 epidemic has become a threat worldwide. Knowledge 
concerning this virus, however, remains minimal. The knowledge 
available is unreliable and data changes are continuous, which can lead 
to differences with the findings of the analysis. Well-annotated data 
from hospital cases and subclinical subjects in normal populations 
might help better explain the pandemic for more reliable and accurate 
results. The pathophysiology, diagnosis, and possible treatment of 
SARS-CoV-2 are outlined in the details given in this study. In the search 
for effective therapies, diagnostics, and vaccines, development activities 
are being increased to resolve the emerging challenges. Clinical work 
on the genetic variation of tissue and population-wide receptors such 
as ACE-2 will remain an ongoing area of study until relevant targets and 
therapies are identified. Although the production of effective COVID-19 
therapies and vaccinations is ongoing, it is recommended to adopt 
proper health habits, including handwashing and social distancing, and 
to follow government recommendations. This would lead to reducing 
the disease’s spread. We hope that researchers will be able to help 
patients build adaptive habits and improve the efficacy of health care 
professionals with the knowledge learned from this study. Only after 
this pandemic stops will one be able to determine the health, social, and 
economic effects of this global catastrophe and we should be able to 
draw lessons for all potential comparable pandemics, notably in terms 
of environmental and global health.
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